PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JFitnich who wrote (43)	3/25/1998 6:05:00 PM
From: Arthur Radley	Read Replies (2) of 626

Hello JF, When I spoke with a company official, I was told the royalty rate was in the 10% range. As for the difference in the EVEREN and STURZA numbers, it is probably an issue of timing of when the drug is approved and the ramp-up of revenues for that first year.I think the $400M @ 10% royalty rate giving TTNP a $40M source of revenue would be fantastic. As you say, this source of money will allow the company to pursue the drug trials and the Parkinson disease with no money problems. From talking with the company, I know they are excited about the potential for the cancer drugs. I wish you had not mentioned XOMA, I'm holding the "puppy" at an average cost of about $7.00. However, if the drug they are working on comes through for them, it will be a bonanza for share holders. Welcome again to PARANOID!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next